Citations

Showing 10 of 108135 citations.

An Assessment of Globe Position Dynamics following Transcranial Lateral and Superior Orbital Wall Resections without Rigid Reconstruction: A Case Series of 55 Patients
Krug, Randall G. , Bradley, Elizabeth A. , Gompel, Jamie J. Van

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | May 21, 2019 | Volume: 81 | Issue: 03 | Pages: 244-250

10.1055/s-0039-1688773 | PMID 32499998 Get It

Background There is no consensus exists regarding which reconstructive approach, if any, should be used after performing transcranial lateral orbital wall resections. Rigid reconstruction is often done to prevent enophthalmos; however, it is not clear if this is a risk with extensive orbital wall resections for transcranial surgery. Objective To assess globe position dynamics in patients that underwent transcranial lateral and superior orbital wall resections without rigid reconstruction to determine if enophthalmos is a significant risk. Methods Preoperative (PO) and postoperative data were retrospectively collected from the electronic medical records of 55 adult patients undergoing lateral and superior orbital wall resections as part of a skull base approach. The globe positions were assessed radiologically at all available time points and used to track relative globe displacements over time. Results An evaluation of PO variables identified a relationship between maximum lesion diameters and globe positions dynamics. The composition of globe position presentations in the population remained relatively stable over time, with only 1 out of 55 patients (1.81%) developing postoperative enophthalmos. An assessment of mean globe displacements revealed improvements in the patients presenting with PO exophthalmos, and stability in the patients presenting with normal PO globe positions. Conclusions Excellent results in long-term postoperative globe position dynamics can be achieved without the use of rigid reconstruction after transcranial lateral and superior orbital wall resections, regardless of the PO globe positioning.
Does community engaged Carnegie status matter for county health rankings in the United States?
Apatu, Emma , Stallings‐Smith, Sericea , Anderson, Laura N. , Spaulding, Aaron , Spaulding, Aaron , Anderson, Laura , Álvarez, Elizabeth

Mayo Clinic

Journal of Public Health | May 21, 2019 | Volume: 43 | Issue: 1 | Pages: 164-171

10.1093/pubmed/fdz066 | PMID 31211380 Get It

Abstract Background Community engagement is commonly used to address social inequities. The Carnegie Foundation offers an optional designation for which U.S. colleges and universities may apply to facilitate better educational outcomes through the institutionalization of community engagement. This study is the first to examine the relationship between Carnegie community engaged status and community health outcomes. Methods Ordinal logistic regression was conducted to investigate the association between the presence of a community engaged institution and county health outcomes, including health behaviors, clinical care relating to access and quality, social and economic factors, and physical environment from the 2016 Robert Wood Johnson County Health Rankings and 2015 New England Resource Center for Higher Education Community engaged list. We examined 820 U.S. counties containing a university or college, 240 of which had a community engaged designation. Results Findings indicated that the presence of a community-engaged institution was positively associated with Clinical Care (OR = 1.99; 95% CI: 1.09, 3.64). Other county health factors were not similarly associated. Conclusions Our findings suggest that community engagement status may be most relevant for achieving better access and quality of clinical care. More research is needed to explore this association in the U.S. and internationally.
Assessment of the Need for a Hematology-Specific Fellowship Curriculum for Advanced Practice Providers Using a Needs-Based Survey
Hwa, Yi L. , Marshall, Ariela L. , Shelly, Jessica L., Colborn, Lisa K., Nowakowski, Grzegorz S. , Lacy, Martha Q. , Marshall, Ariela

Mayo Clinic

Journal of Oncology Practice | May 21, 2019 | Volume: 15 | Issue: 7 | Pages: e593-e599

10.1200/jop.18.00697 | PMID 31112482 Get It

PURPOSE: Subspecialty training programs rarely are available for advanced practice providers (APPs). New curricula are needed to prepare APPs with the skills and knowledge required to deliver high-quality care in hematology and blood and marrow transplantation (BMT). METHODS: A Web-based needs assessment survey was distributed to APPs currently working in hematology and BMT at three Mayo Clinic sites (Rochester, MN; Scottsdale, AZ; and Jacksonville, FL). The survey assessed participants’ perceptions of readiness to practice in hematology after completion of their APP education and identified APP learning needs. RESULTS: Of 68 APPs, 49 (72%; 34 nurse practitioners, 15 physician assistants) completed the survey. Twenty-eight APPs (57%) were new graduates, and 17 (35%) had no prior experience in hematology/BMT. All APPs held a master’s degree or higher (doctorate, 31%). Thirty-nine (80%) reported that less than 5% of their APP school curriculum was hematology focused. More than 90% felt unprepared to practice in hematology or BMT after their APP education and believed that hematology-specific training could improve their competency as providers and positively affect job satisfaction. APPs reported that they would like more formal training in the following areas of clinical focus: malignant and benign hematologic disorders, hematopathology, palliative care, transfusion medicine, infectious disease, and hematology-related pharmacology. They also preferred the following learning strategies: active learning from patient care, case-based teaching, and experience during hospital rounds. CONCLUSION: This needs-based assessment project confirmed the necessity to develop a hematology-specific fellowship for APPs and helped to optimize the curriculum.
Improved Interpretability of Machine Learning Model Using Unsupervised Clustering: Predicting Time to First Treatment in Chronic Lymphocytic Leukemia
Chen, David , Ngufor, Che G, Goyal, Gaurav , Go, Ronald S. , Parikh, Sameer A. , Ngufor, Che

Mayo Clinic

JCO Clinical Cancer Informatics | May 21, 2019 | Volume: No volume available | Issue: 3 | Pages: 1-11

10.1200/cci.18.00137 | PMID 31112417 Get It

PURPOSE Time to event is an important aspect of clinical decision making. This is particularly true when diseases have highly heterogeneous presentations and prognoses, as in chronic lymphocytic lymphoma (CLL). Although machine learning methods can readily learn complex nonlinear relationships, many methods are criticized as inadequate because of limited interpretability. We propose using unsupervised clustering of the continuous output of machine learning models to provide discrete risk stratification for predicting time to first treatment in a cohort of patients with CLL. PATIENTS AND METHODS A total of 737 treatment-naïve patients with CLL diagnosed at Mayo Clinic were included in this study. We compared predictive abilities for two survival models (Cox proportional hazards and random survival forest) and four classification methods (logistic regression, support vector machines, random forest, and gradient boosting machine). Probability of treatment was then stratified. RESULTS Machine learning methods did not yield significantly more accurate predictions of time to first treatment. However, automated risk stratification provided by clustering was able to better differentiate patients who were at risk for treatment within 1 year than models developed using standard survival analysis techniques. CONCLUSION Clustering the posterior probabilities of machine learning models provides a way to better interpret machine learning models.
Assessment and Validation of a Phenotype-Enhanced Variant Classification Framework to Promote or Demote RYR2 Missense Variants of Uncertain Significance
Giudicessi, John R. , Lieve, Krystien V.V. , Rohatgi, Ram K., Tester, David J. , Werf, Christian van der , Wilde, Arthur A.M. , Ackerman, Michael J. , van der Werf, Christian , Koca, Faruk , Bos, J. Martijn , Lieve, Krystien V

Mayo Clinic

Circulation: Genomic and Precision Medicine | May 21, 2019 | Volume: 12 | Issue: 5 | Pages: No page available

10.1161/circgen.119.002510 | PMID 31112425 Get It

Background Many rare, potentially pathogenic, RYR2 variants identified in individuals with clinically definite catecholaminergic polymorphic ventricular tachycardia are classified ambiguously as variants of uncertain significance (VUS). We aimed to determine if a phenotype-enhanced variant classification approach could reduce the burden of RYR2 VUS encountered during clinical genetic testing. Methods This retrospective study was conducted in 84 RYR2 -positive individuals from the Mayo Clinic (Rochester, MN) and validated in 149 RYR2 -positive individuals from Amsterdam University Medical Center (Amsterdam, NL). Using a newly developed diagnostic scorecard, the pretest clinical probability of catecholaminergic polymorphic ventricular tachycardia was determined for all RYR2 -positive individuals. Each RYR2 variant was then readjudicated using a phenotype-enhanced American College of Medical Genetics approach that incorporates new criteria that reflect the phenotypic strength associated with each individual RYR2 variant. Results Overall, 72 distinct RYR2 variants were identified among the 84 Mayo Clinic (39 unique) and 149 Amsterdam University Medical Center (30 unique) cases. Three variants were present in both cohorts. American College of Medical Genetics guidelines classified 47% of all RYR2 variants as VUS. In the Mayo Clinic cohort, readjudication using amended phenotype-enhanced American College of Medical Genetics standards dropped the VUS rate significantly (20/42 [48%] versus 3/42 [7%]; P <0.001) with 13/20 (65%) RYR2 VUS promoted to likely pathogenic and 4/20 (20%) demoted to likely benign. A similar drop in VUS rate (14/33 [42%] versus 3/33 [9%]; P =0.001) was observed in the Amsterdam University Medical Center validation cohort with 10/14 (71%) RYR2 VUS promoted to likely pathogenic and 1/14 (7%) demoted to likely benign. Conclusions This multicenter study illustrates the potential utility of phenotype-enhanced variant classification in catecholaminergic polymorphic ventricular tachycardia.
Essential Office Procedures for Medicare Patients in Primary Care: Comparison With Family Medicine Residency Training
Poulin, Eric A., Swartz, Andrew W. , O'Grady, J. , Kersten, Mclean Phillip M., Angstman, Kurt B. , O'Grady, Jason S, O'Grady, Jason S

Mayo Clinic

Family Medicine | May 21, 2019 | Volume: 51 | Issue: 7 | Pages: 574-577

10.22454/fammed.2019.659478 | PMID 31125421 Get It

Background and Objectives: Demographic trends show an increasing older adult population. Therefore, family medicine training programs may need to reevaluate how well their residents perform clinic procedures essential to older adults. Our objective was to compare the rates of the most frequently performed clinic procedures for Medicare patients in a large multiregional health care system (MRHCS) with those in a family medicine residency clinic. Methods: In this retrospective cohort study, Current Procedural Terminology coding data were queried from the billing systems of an MRHCS (the control group) and a family medicine residency clinic (the study group) for a 3-year period. The primary outcome was the procedural rate ratios per 1,000 office visits for the 10 most common clinic procedures in the MRHCS billed to Medicare. Results: The study group consisted of 19,099 office visits by Medicare patients to the residency clinic; the control group consisted of 2,034,188 visits to the MRHCS. Except for large joint injection, procedural rates were significantly different for the other nine procedures (destruction of benign skin lesions, nail care, punch or shave skin biopsy, removal of impacted cerumen, wound debridement of skin, Unna boot application, excision of skin lesion, paring of corn or callus, and insertion of bladder catheter). The rate of skin excision was higher in the residency clinic than in the MRHCS but lower for the other eight procedures. Conclusions: These data suggest that teaching programs may need to adapt to meet the current and future practice needs of this increasing patient population.
Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study
Ramchandren, Radhakrishnan , Domingo‐Doménech, Eva , Rueda, Antonio , Feldman, Tatyana , Lee, Hun Ju , Provencio, Mariano , Sillaber, Christian, Cohen, Jonathon B. , Willenbacher, Wolfgang , Ligon, Azra H. , Sacchi, Mariana, Sumbul, Anne, Armand, Philippe , Ansell, Stephen M. , Domingo-Domenech, Eva , Trněný, Marek , Savage, Kerry J. , Ouyang, Jing , Redd, Robert , Rodig, Scott J , Shipp, Margaret Ann

Mayo Clinic

Journal of Clinical Oncology | May 21, 2019 | Volume: 37 | Issue: 23 | Pages: 1997-2007

10.1200/jco.19.00315 | PMID 31112476 Get It

PURPOSE Nivolumab, an anti–programmed death-1 monoclonal antibody, has demonstrated frequent and durable responses in relapsed/refractory classic Hodgkin lymphoma (cHL). We report results from Cohort D of the CheckMate 205 trial, which assessed nivolumab monotherapy followed by nivolumab plus doxorubicin, vinblastine, and dacarbazine (N-AVD) for newly diagnosed cHL. METHODS Patients 18 years of age or older with untreated, advanced-stage (defined as III to IV and IIB with unfavorable risk factors) cHL were eligible for Cohort D of this multicenter, noncomparative, phase II trial. Patients received nivolumab monotherapy for four doses, followed by 12 doses of N-AVD; all doses were every 2 weeks, and nivolumab was administered at 240 mg intravenously. The primary end point was safety. Efficacy end points included objective response rate and modified progression-free survival, defined as time to disease progression/relapse, death, or next therapy. Chromosome 9p24.1 alterations and programmed death-ligand 1 expression were assessed in Hodgkin Reed-Sternberg cells in evaluable patients. RESULTS A total of 51 patients were enrolled and treated. At diagnosis, 49% of patients had an International Prognostic Score of 3 or greater. Overall, 59% experienced a grade 3 to 4 treatment-related adverse event. Treatment-related febrile neutropenia was reported in 10% of patients. Endocrine immune-mediated adverse events were all grade 1 to 2 and did not require high-dose corticosteroids; all nonendocrine immune-mediated adverse events resolved (most commonly, rash; 5.9%). At the end of therapy, the objective response rate (95% CI) per independent radiology review committee was 84% (71% to 93%), with 67% (52% to 79%), achieving complete remission (five patients [10%] were nonevaluable and counted as nonresponders). With a minimum follow-up of 9.4 months, 9-month modified progression-free survival was 92%. Patients with higher-level Hodgkin Reed-Sternberg programmed death-ligand 1 expression had more favorable responses to N-AVD ( P = .041). CONCLUSION Nivolumab followed by N-AVD was associated with promising efficacy and safety profiles for newly diagnosed, advanced-stage cHL.
Cost-Effectiveness of Active Surveillance, Radical Prostatectomy and External Beam Radiotherapy for Localized Prostate Cancer: An Analysis of the ProtecT Trial
Sharma, Vidit , Wymer, Kevin , Barocas, Daniel A. , Thompson, R. Houston, Karnes, R. Jeffrey , Boorjian, Stephen A. , Borah, Bijan J.

Mayo Clinic

Journal of Urology | May 21, 2019 | Volume: 202 | Issue: 5 | Pages: 964-972

10.1097/ju.0000000000000345 | PMID 31112105 Get It

Dosimetric comparison of distal esophageal carcinoma plans for patients treated with small‐spot intensity‐modulated proton versus volumetric‐modulated arc therapies
Liu, Chenbin , Bhangoo, R.S. , Yu, Nathan Y. , Shan, Jie , Chiang, Jennifer S. , Ding, Julia, Rule, William G., Korte, Shawn M., Lara, Pedro, Ding, Xiaoning, Hu, Yanle , DeWees, T.A. , Ashman, Jonathan B. , Bhangoo, Ronik S, Ding, Julia X, Korte, Shawn, Bues, Martin , DeWees, Todd, DeWees, Todd A , Sio, Terence T. , Liu, Wei

Mayo Clinic

Journal of Applied Clinical Medical Physics | May 21, 2019 | Volume: 20 | Issue: 7 | Pages: 15-27

10.1002/acm2.12623 | PMID 31112371 Get It

BackgroundEsophageal carcinoma is the eighth most common cancer in the world. Volumetric‐modulated arc therapy (VMAT) is widely used to treat distal esophageal carcinoma due to high conformality to the target and good sparing of organs at risk (OAR). It is not clear if small‐spot intensity‐modulated proton therapy (IMPT) demonstrates a dosimetric advantage over VMAT. In this study, we compared dosimetric performance of VMAT and small‐spot IMPT for distal esophageal carcinoma in terms of plan quality, plan robustness, and interplay effects.Methods35 distal esophageal carcinoma patients were retrospectively reviewed; 19 patients received small‐spot IMPT and the remaining 16 of them received VMAT. Both plans were generated by delivering prescription doses to clinical target volumes (CTVs) on phase‐averaged 4D‐CT's. The dose‐volume‐histogram (DVH) band method was used to quantify plan robustness. Software was developed to evaluate interplay effects with randomized starting phases for each field per fraction. DVH indices were compared using Wilcoxon rank‐sum test. For fair comparison, all the treatment plans were normalized to have the same CTVhigh D95% in the nominal scenario relative to the prescription dose.ResultsIn the nominal scenario, small‐spot IMPT delivered statistically significantly lower liver Dmean and V30Gy[RBE], lung Dmean, heart Dmean compared with VMAT. CTVhigh dose homogeneity and protection of other OARs were comparable between the two treatments. In terms of plan robustness, the IMPT and VMAT plans were comparable for kidney V18Gy[RBE], liver V30Gy[RBE], stomach V45Gy[RBE], lung Dmean, V5Gy[RBE], and V20Gy[RBE], cord Dmax and , liver Dmean, heart V20Gy[RBE], and V30Gy[RBE], but IMPT was significantly worse for CTVhigh D95%, , and D5%‐D95%, CTVlow D95%, heart Dmean, and V40Gy[RBE], requiring careful and experienced adjustments during the planning process and robustness considerations. The small‐spot IMPT plans still met the standard clinical requirements after interplay effects were considered.ConclusionsSmall‐spot IMPT decreases doses to heart, liver, and total lung compared to VMAT as well as achieves clinically acceptable plan robustness. Our study supports the use of small‐spot IMPT for the treatment of distal esophageal carcinoma.
Gadolinium-based contrast agents: A clinically significant analytical interference in inductively coupled plasma mass spectrometry elemental analysis
Day, Patrick L. , Erdahl, Sarah A , Eckdahl, Steve, Bornhorst, Joshua A. , Jannetto, Paul J. , Day, Patrick, Erdahl, Sarah, Bornhorst, Joshua, Bornhorst, Joshua , Day, Patrick

Mayo Clinic

Annals of Clinical Biochemistry: International Journal of Laboratory Medicine | May 21, 2019 | Volume: 56 | Issue: 6 | Pages: 638-645

10.1177/0004563219856031 | PMID 31112390 Get It

Background Gadolinium-based contrast agents (GBCAs) have been used in magnetic resonance imaging for the past 30 years, where they have significantly improved the effectiveness of imaging studies. However, the increased usage of gadolinium in the medical community has also resulted in unexpected interferences in other laboratory assays. This has been particularly the case in clinical elemental analysis using inductively coupled plasma mass spectrometry (ICP-MS). Methods By conducting ICP-MS interference experiments, we describe how gadolinium interferes with elemental analysis by space charge effect, double charge effect and the creation of polyatomic interferences. Additionally, by reviewing more than a year of reference laboratory data from our laboratory information system, we determined the number of elemental tests cancelled due to gadolinium interference. Results Interference experiments show that gadolinium normally found in GBCAs can interfere with heavy metals, platinum and selenium analysis of biological fluids using ICP-MS. Within one year, our institution’s metals laboratory had to cancel 42 selenium serum tests and 19 heavy metal urine panels due to potential interference caused by gadolinium. Conclusions GBCAs will continue to be utilized in hospitals around the world. However, clinical laboratories should be wary of potential interferences caused by GBCAs. Relevant interferences include space charge effect, double charge interference, and the formation of polyatomic interferences caused by gadolinium. These interferences can negatively affect patient care by resulting in cancelled laboratory tests and causing patients to have blood redrawn and analysed at a later date leading to delays in their diagnosis/treatment.